ICO.V - iCo Therapeutics Inc.

TSXV - TSXV Delayed Price. Currency in CAD

iCo Therapeutics Inc.

777 Hornby Street
6th Floor
Vancouver, BC V6Z 1S4

Full Time Employees

Key Executives

Mr. Andrew J. Rae BSc, MBACo-Founder, CEO, Pres & Director309.5kN/A50
Mr. Michael Liggett CPA, CA, Bsc. Pharm.CFO, Corp. Sec. & Director19.72kN/A57
Dr. Peter Hnik M.D., MHScChief Medical Officer196.64kN/A61
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008 (Bertilimumab), a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, and diabetics. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Corporate Governance

iCo Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.